The award-winning, venture-backed company is developing novel biologics to treat and prevent infections, with a focus on improving the quality of life for patients with Primary Immunodeficiency Diseases. Lactiga is using human milk antibodies to create the next-generation of anti-infectives that can battle even the world’s most dangerous pathogens, including SARS-CoV-2. Their biotherapeutics are intended to prevent mucosal infections for patients with PIDD, helping immunodeficient and immunocompromised people around the world experience normal lives, free from invasive treatments. Lactiga has earned awards, media attention, and is participating in the On Deck Health (ODH2) cohort.